Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center
Articles
Impact of Recent Clinical Data on Treatment for HER2+ MBC
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
CDK4/6 Inhibitors for Triple-Positive Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
Treatment Choice for Patient Relapsing With Brain Metastases
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
HER2CLIMB: Brain Metastases Data
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
HER2+ Early Stage Breast Cancer With Residual Invasive Disease
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
TRAIN-2: Anthracyclines in HER2+ Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
APHINITY and ExteNET Trials for Early-Stage Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
HER2+ Early-Stage Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
Guidelines and Approaches to HER2 Testing for Breast Cancer
Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center;Carey K. Anders, MD, Duke Cancer Institute;Virginia Kaklamani, MD, University of Texas Health Science Center;Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center;Mark D. Pegram, MD, Stanford Cancer Center
June 30th 2020Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
